Pfizer’s CEO on leading after a moonshot—and making deals with Trump
In today’s CEO Daily: Fortune Editor-in-Chief Alyson Shontell interviews Pfizer CEO Albert Bourla. The big story: Target’s incoming CEO speaks out about the immigration crackdown in the retailer’s home state. The markets: Up globally, with U.S. markets set to climb at the open. Plus: All the news and watercooler chat from Fortune. Good morning. What […]
GLP-1 drugs don’t work for everyone. But personalized obesity care in the future might
As doctors learn why GLP-1s don’t work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now. (Image credit: Tatsiana Volkava)
Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial
Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase 3 studies in the coming weeks.
Havas’ GLP-1 Consultancy takes center stage at 1 Billion Followers Summit in Dubai
As GLP-1 adoption accelerates across the Middle East, Havas brings a unique specialized strategic cultural lens to the rapidly evolving metabolic economy
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
SAN FRANCISCO–(BUSINESS WIRE)– #SUD–Baseline Therapeutics, Inc. (“Baseline”), a clinical-stage biotechnology company developing addiction therapeutics, today announced the launch of the company to advance a new generation of pharmacotherapies for substance use disorders. Baseline’s lead program, BT-001, is a best-in-class, once-weekly GLP-1 receptor agonist (GLP-1RA) candidate being developed for alcohol use disorder (AUD), with additional substance […]
GLP-1 Meds Are Bringing Back Our Eating Disorders
STAT+: New startup to develop a GLP-1 drug for addiction
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A new startup focused on GLP-1 drugs launched today, but unlike the dozens of other GLP-1 companies, this one isn’t studying weight loss. The need-to-know this morning Roche plans to launch Phase […]
Where Will Eli Lilly Be in 10 Years?
Key Points The pharmaceutical industry has a well-structured cycle. Eli Lilly is currently benefiting from the early stages of the cycle. In 10 years, if not sooner, investors will begin to worry about Eli Lilly’s future beyond GLP-1 drugs. 10 stocks we like better than Eli Lilly › If you follow the news at all, […]
Do GLP-1s Have Deleterious Effects on Muscle?
Emerging evidence suggests that GLP-1 receptor agonists may improve muscle quality as body weight and lean mass decline. Medscape Gastroenterology
Roche, trailing in obesity, showcases new data for GLP-1 shot
A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.